Expression of interferon type-I receptor isoforms, clinical response and development of neutralizing antibodies in multiple sclerosis patients – results of a prospective study

Author:

Bauer Angelika,Rudzki Dagmar,Auer Michael,Hegen Harald,Deisenhammer Florian

Abstract

AbstractOne of the first line treatments for relapsing-remitting multiple sclerosis (RRMS) is interferon-β (IFNb), a cytokine with immune-modulatory effects. There is a high degree of variability in the response to the drug which is, among other factors, due to the presence of neutralizing antibodies (NABs) occurring late during therapy.The objective of this study was to determine whether the response to IFNb therapy and NAB development can be predicted based on the expression levels of the type-I interferon receptors IFNAR1, IFNAR2a, IFNAR2b, and IFNAR2c before start of treatment. The IFNAR expression levels in 163 samples of patients with relapsing-remitting MS were measured by real-time polymerase chain reaction (PCR).Pre-treatment IFNAR2c expression levels were somewhat lower in patients who developed NAB during treatment compared to NAB-negative patients. No significant differences in the expression levels of other IFNAR subtypes and isotypes were found. Baseline IFNAR levels were not predictive of the clinical response after 2 years.Overall, there was a small, non-significant effect of IFNAR2c baseline levels on NAB development but no relation to clinical endpoints. Lower expression of IFNAR2c receptors could lead to higher IFNb levels inducing a higher rate of antibody response.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3